<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020588</url>
  </required_header>
  <id_info>
    <org_study_id>II3/02/0618</org_study_id>
    <nct_id>NCT04020588</nct_id>
  </id_info>
  <brief_title>Anti-inflammatories and Adolescent Schizophrenia</brief_title>
  <official_title>Effect of Anti-inflammatory Treatments on the Symptoms, Cognition, and Functioning of Adolescents With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and
      cognition of adolescents with schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be evaluated to confirm the diagnosis of schizophrenia, duration of the disease
      and record a history of atopic diseases or recurrent infections throughout life. The PANSS,
      PSP, and MCCB battery scales will be administered. A blood sample will be taken for the
      determination of markers of inflammation before the start of pharmacological treatment.

      Patients will start the antipsychotic medication assigned by their treating physician. They
      will also be assigned randomly to the treatment arm. The study drug will be provided by the
      research team under the presentation of capsules containing Celecoxib 200 mg, Minocycline 100
      mg or Placebo, and patients will be instructed to take one capsule every 12 hrs daily.

      The patient will be reassessed with PANSS, PSP, and MCCB after completing 6 weeks of
      pharmacological treatment, type and dose of medication will be recorded and serum markers of
      inflammation will be determined again.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom severity: Positive and Negative Syndrome Scale score</measure>
    <time_frame>six weeks</time_frame>
    <description>Change in the Positive and Negative Syndrome Scale score, which comprises 33 items which can be scored from 1 (absent) to 7 (extreme), evaluating an array of symptoms including positive, negative, neuromotor, depressive and anxious, and involves the use of data from patient reports, caregiver reports, and clinical observations. The total score is the sum or all the items, the maximum score is 231. The higher values represent a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognition: MATRICS Consensus Cognitive Battery (MCCB) scores</measure>
    <time_frame>six weeks</time_frame>
    <description>Change in MCCB scores. The MCCB is comprised of 9 tests that reflect 7 dimensions of neurocognitive dysfunction in schizophrenia, including: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, and Reasoning and Problem Solving and Social Cognition. The MCCB scoring program yields the domain scores and a composite score which are standardized to the same T-score measurement scale with a mean of 50 and an SD of 10 based upon the normative data.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline 100 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 200mg</intervention_name>
    <description>Will be administered for 6 weeks</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Minocycline 100 mg</other_name>
    <other_name>Minocycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Will be administered for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline 100mg</intervention_name>
    <description>Will be administered for 6 weeks</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Minocycline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizophreniform disorder.

          -  Patients in their first psychotic episode or previously diagnosed

          -  No specific pharmacological treatment (antipsychotic at therapeutic doses in regular
             doses) in the previous two weeks.

          -  Have a responsible parent or guardian.

        Exclusion Criteria:

          -  Active infection

               -  Chronic somatic diseases, including autoimmune diseases

               -  Comorbidity with anorexia, substance use disorders

               -  Pregnancy

               -  Use of anti-inflammatory medications or antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosa Ulloa, M.D</last_name>
    <phone>+525555739161</phone>
    <email>eulloa@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Psiquiatrico Infantil</name>
      <address>
        <city>Mexico City</city>
        <state>Ni Ee.uu. Ni Canad√°</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa E Ulloa, M.D.</last_name>
      <phone>5555739161</phone>
      <email>eulloa@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>adolescents</keyword>
  <keyword>inflammation</keyword>
  <keyword>anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

